A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
Status:
Completed
Trial end date:
2020-12-22
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and efficacy of 3 different doses of
CTP-692 administered once daily for 12 weeks to adult patients with schizophrenia on stable
dopaminergic antipsychotic medication.